---
layout: default
title: Testosterone
parent: 僅模型預測 (L5)
nav_order: 961
evidence_level: L5
indication_count: 10
---

# Testosterone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Testosterone: From Androgen Deficiency to Polysomy of X Chromosome

## One-Sentence Summary

> Testosterone (DrugBank DB00624) is the principal endogenous androgen, used clinically for androgen replacement in conditions of testosterone deficiency such as male hypogonadism.
> The TxGNN model predicts it may be relevant to **Polysomy of X Chromosome** (e.g., Klinefelter-type karyotypes),
> but this specific prediction currently has **no supporting clinical trials or literature** in the evidence pack — it is a model-only signal.

*Note: The evidence pack returned no regulatory record for testosterone's original indication or mechanism of action (both flagged as data gaps). The "androgen deficiency" indication above reflects well-established general pharmacology, not a value confirmed by this evidence pack.*

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in evidence pack (see Data Gap DG002); testosterone is generally used for androgen/testosterone deficiency |
| Predicted New Indication | Polysomy of X Chromosome |
| TxGNN Prediction Score | 94.88% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed (未上市) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for testosterone in this evidence pack (Data Gap DG002, severity High). Based on general pharmacological knowledge, testosterone is the primary endogenous androgen and is used therapeutically for androgen replacement in states of testosterone deficiency, most commonly male hypogonadism.

Polysomy of X chromosome — which clinically includes conditions such as Klinefelter syndrome (47,XXY) and its variants — is well known to present with primary hypogonadism and low endogenous testosterone due to testicular dysfunction. Androgen replacement therapy is, in fact, standard clinical practice for these patients. Mechanistically, this predicted link is therefore plausible and consistent with established endocrinology, even though it functions more as a confirmation of known practice than a novel repurposing hypothesis.

However, it should be noted that for this specific run, **no clinical trials or literature were retrieved** to substantiate the association for "polysomy of X chromosome" specifically. The evidence pack's other lower-ranked predictions (e.g., rank 2 "tetragametic chimerism," rank 4 "testicular regression syndrome," rank 10 "primary ovarian failure") do carry supporting literature and/or trials involving testosterone, but these are not the top-ranked candidate and fall outside the scope of this single-indication report.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(All safety fields — key warnings, contraindications, drug interactions — are recorded as data gaps in this evidence pack. Data Gap DG001 (TFDA/HSA label warnings and contraindications) is flagged as Blocking, meaning the drug cannot proceed to the S1 safety pre-screening stage until this is resolved.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (polysomy of X chromosome) has no supporting clinical trial or literature evidence in this evidence pack — it is a model-only (L5) signal. Combined with a Blocking data gap on label warnings/contraindications, there is insufficient evidence to advance this specific indication.

**To proceed, the following is needed:**
- TFDA/HSA package insert warnings and contraindications (DG001, Blocking) — required before any S1 safety pre-screening
- Testosterone mechanism of action data from DrugBank (DG002, High)
- Regulatory record of testosterone's original approved indication(s) in Singapore, or confirmation that it is genuinely unregistered
- Targeted literature/trial search specifically on testosterone use in Klinefelter syndrome / X-chromosome polysomy populations, since the current search returned none for this exact term despite plausible clinical precedent
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

